NCT07530666

Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia

Phase I/II Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of DS010 in Patients With Cancer Cachexia

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 58 (estimated)
• Sponsor: Dartsbio Pharmaceuticals Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A study to evaluate the safety, tolerability, and preliminary efficacy of DS010 in patients with cancer and cachexia

Conditions

• Cancer
• Cachexia

Interventions

Type	Name	Description
DRUG	DS010 injection	Once every 3 weeks intravenously injection
DRUG	DS010 injection	Once every 3 weeks intravenously injection
DRUG	DS010 injection	Once every 3 weeks intravenously injection
DRUG	DS010 injection	Once every 3 weeks intravenously injection
DRUG	DS010 injection	Once every 3 weeks intravenously injection
DRUG	DS010 injection	Once every 3 weeks intravenously injection
DRUG	DS010 injection	Once every 3 weeks or once every 4 weeks intravenously injection
DRUG	DS010 injection	Once every 3 weeks or once every 4 weeks intravenously injection
DRUG	DS010 injection	Once every 3 weeks or once every 4 weeks intravenously injection
DRUG	DS010 injection	Once every 3 weeks or once every 4 weeks intravenously injection

Timeline

• Start date: 2026-04-30
• Primary completion: 2027-10-30
• Completion: 2028-04-30
• First posted: 2026-04-15
• Last updated: 2026-04-15

Locations

1 site across 1 country: China